PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by BlackRock Inc.

Share on StockTwits

BlackRock Inc. lifted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 9.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,502,671 shares of the biopharmaceutical company’s stock after buying an additional 394,773 shares during the period. BlackRock Inc. owned approximately 7.64% of PTC Therapeutics worth $202,619,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sector Gamma AS boosted its stake in shares of PTC Therapeutics by 17.8% during the second quarter. Sector Gamma AS now owns 229,498 shares of the biopharmaceutical company’s stock worth $10,327,000 after buying an additional 34,755 shares during the period. Aperio Group LLC acquired a new stake in shares of PTC Therapeutics during the second quarter worth about $168,000. Emerald Advisers LLC boosted its stake in shares of PTC Therapeutics by 29.6% during the second quarter. Emerald Advisers LLC now owns 388,010 shares of the biopharmaceutical company’s stock worth $17,460,000 after buying an additional 88,579 shares during the period. RMB Capital Management LLC acquired a new stake in shares of PTC Therapeutics during the second quarter worth about $1,423,000. Finally, Candriam Luxembourg S.C.A. boosted its stake in shares of PTC Therapeutics by 38.5% during the second quarter. Candriam Luxembourg S.C.A. now owns 640,523 shares of the biopharmaceutical company’s stock worth $28,697,000 after buying an additional 178,000 shares during the period. Institutional investors and hedge funds own 94.56% of the company’s stock.

Shares of NASDAQ:PTCT opened at $44.88 on Wednesday. The company has a quick ratio of 4.30, a current ratio of 4.40 and a debt-to-equity ratio of 0.44. The company has a market cap of $2.69 billion, a P/E ratio of -24.39 and a beta of 1.88. PTC Therapeutics, Inc. has a 52 week low of $27.53 and a 52 week high of $48.81. The company has a 50-day moving average price of $38.36 and a 200 day moving average price of $41.36.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.15). The firm had revenue of $71.40 million during the quarter, compared to analyst estimates of $72.03 million. PTC Therapeutics had a negative net margin of 74.86% and a negative return on equity of 31.92%. PTC Therapeutics’s revenue for the quarter was up 33.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.06) EPS. Analysts expect that PTC Therapeutics, Inc. will post -2.86 EPS for the current year.

Several brokerages have recently weighed in on PTCT. ValuEngine upgraded shares of PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Barclays reiterated a “hold” rating and set a $43.00 target price on shares of PTC Therapeutics in a research note on Monday, August 12th. Zacks Investment Research downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Royal Bank of Canada restated a “buy” rating on shares of PTC Therapeutics in a research report on Tuesday, September 24th. Finally, Cowen restated a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $54.00.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

See Also: Depreciation

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.